OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

1 Projects | 1 Researchers | $1,997,865 Invested

2020

LEXEO Therapeutics, Inc.

Ronald Crystal, MD

Phase I Clinical Trial for the AAV mediated treatment of APOE4 homozygous Alzheimer’s Disease

  • Funding Amount: $1,997,865
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: zzAPOE
  • Status: Active